Andrew Reardon, CLO & Secretary at LIGAND PHARMACEUTICALS INC (LGND), sold 9,500 shares at $197.70 ($2.0M) on 2026-03-04, disclosed to the SEC on 2026-03-06.
Open-market sale of $2.0M LGND by CLO & Secretary. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $197.70 | 100 | $20K | 1.0% |
| 2 | $197.70 | 100 | $20K | 1.0% |
| 3 | $199.00 | 100 | $20K | 1.0% |
| 4 | $199.01 | 100 | $20K | 1.0% |
| 5 | $199.96 | 207 | $41K | 2.1% |
| 6 | $199.96 | 207 |
| $41K |
| 2.1% |
| 7 | $200.62 | 93 | $19K | 1.0% |
| 8 | $200.62 | 93 | $19K | 1.0% |
| 9 | $201.70 | 300 | $61K | 3.1% |
| 10 | $204.17 | 200 | $41K | 2.1% |
| 11 | $205.18 | 460 | $94K | 4.8% |
| 12 | $205.18 | 460 | $94K | 4.8% |
| 13 | $206.37 | 340 | $70K | 3.6% |
| 14 | $206.37 | 340 | $70K | 3.6% |
| 15 | $207.01 | 612 | $127K | 6.5% |
| 16 | $207.01 | 612 | $127K | 6.5% |
| 17 | $208.12 | 1,446 | $301K | 15.3% |
| 18 | $208.12 | 1,446 | $301K | 15.3% |
| 19 | $208.87 | 1,142 | $239K | 12.2% |
| 20 | $208.87 | 1,142 | $239K | 12.2% |
| Total | $206.55 avg | 9,500 | $2.0M | 100% |
| Filing → |
| LGND | SELL | 2026-08-04 | $1.4M | — | Filing → |
| LGND | SELL | 2026-07-06 | $1.6M | — | Filing → |
| LGND | SELL | 2026-06-02 | $1.1M | — | Filing → |